CA2302169A1 - Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene - Google Patents

Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene Download PDF

Info

Publication number
CA2302169A1
CA2302169A1 CA002302169A CA2302169A CA2302169A1 CA 2302169 A1 CA2302169 A1 CA 2302169A1 CA 002302169 A CA002302169 A CA 002302169A CA 2302169 A CA2302169 A CA 2302169A CA 2302169 A1 CA2302169 A1 CA 2302169A1
Authority
CA
Canada
Prior art keywords
androgen
peptide
amino acids
tracts
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002302169A
Other languages
English (en)
Inventor
Marianne D. Sadar
Nicholas Bruchovsky
Peter W. Gout
Robert Snoek
Nasrin R. Mawji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2302169A1 publication Critical patent/CA2302169A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'activation indépendante de l'androgène du récepteur d'androgène est localisée dans la région comprenant les acides aminés 234-391 de la protéine du récepteur d'androgène humain. L'invention concerne des peptides dérivés et des acides nucléiques codant pour ces peptides. Ces peptides sont utiles comme domaines d'activation, comme inhibiteurs de l'activation indépendante des androgènes du récepteur d'androgène, et comme agents thérapeutiques pour des pathologies d'origine androgénique telles que le cancer de la prostate. L'invention concerne en outre des procédés permettant la sélection de composés affectant l'activation indépendante de l'androgène du récepteur d'androgène.
CA002302169A 1998-06-30 1999-06-30 Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene Abandoned CA2302169A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9187198P 1998-06-30 1998-06-30
US60/091,871 1998-06-30
PCT/CA1999/000604 WO2000001813A2 (fr) 1998-06-30 1999-06-30 Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene

Publications (1)

Publication Number Publication Date
CA2302169A1 true CA2302169A1 (fr) 2000-01-13

Family

ID=22230037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002302169A Abandoned CA2302169A1 (fr) 1998-06-30 1999-06-30 Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene

Country Status (3)

Country Link
AU (1) AU4494399A (fr)
CA (1) CA2302169A1 (fr)
WO (1) WO2000001813A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003018987A (ja) * 2001-06-25 2003-01-21 Okazaki National Research Institutes 遺伝子導入細胞及びそれを用いた撹乱物質の検出法
US20100189776A1 (en) * 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
WO2009033212A1 (fr) * 2007-09-11 2009-03-19 Christopher Hovens Utilisation de protéines de liaison aux œstrogènes et aux androgènes dans des procédés et compositions pour le traitement de cancers gynécologiques
FR2938334A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
RU2015107733A (ru) 2008-07-02 2015-06-27 Бритиш Коламбиа Кэнсер Эйдженси Бранч Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения
RU2519948C2 (ru) 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2012139039A2 (fr) 2011-04-08 2012-10-11 British Columbia Cancer Agency Branch Composés de bisphénol et leurs procédés d'utilisation
EP2744773B1 (fr) 2011-08-19 2016-11-02 British Columbia Cancer Agency Branch Composés d'éthers de bisphénol fluorés et leurs procédés d'utilisation
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
MX347705B (es) 2013-05-10 2017-05-09 British Columbia Cancer Agency Branch Derivados de ester moduladores del receptor de androgeno y metodos para su uso.
EP3044197B1 (fr) 2013-09-09 2018-11-07 British Columbia Cancer Agency Branch Composés halogénés pour imagerie et traitement du cancer, et procédés pour leur utilisation
CA2948643C (fr) 2014-05-30 2022-09-06 British Columbia Cancer Agency Branch Modulateurs du recepteur androgenique et leurs methodes d'utilisation
DK3245193T3 (da) 2015-01-13 2022-03-07 British Columbia Cancer Agency Branch Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
CA3032549A1 (fr) * 2016-08-08 2018-02-15 Olipass Corporation Oligonucleotides antisens du recepteur des androgenes
WO2019226991A1 (fr) 2018-05-25 2019-11-28 Essa Pharma, Inc. Modulateurs du récepteur des androgènes et leurs procédés d'utilisation
SG11202103325WA (en) 2018-10-18 2021-05-28 Essa Pharma Inc Androgen receptor modulators and methods for their use
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
WO2023046283A1 (fr) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Composés et leur utilisation dans une méthode de modulation de l'activité transcriptionnelle d'ar (récepteur des androgènes)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
EP0577932A3 (fr) * 1992-05-08 1995-04-19 American Cyanamid Co Développement d'un "screening" basé en mécanisme pour identifier agonistes et antagonistes du récepteur d'androgène.
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same

Also Published As

Publication number Publication date
WO2000001813A2 (fr) 2000-01-13
AU4494399A (en) 2000-01-24
WO2000001813A3 (fr) 2000-04-13

Similar Documents

Publication Publication Date Title
CA2302169A1 (fr) Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene
Rishi et al. Estradiol regulation of the human retinoic acid receptor α gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs
Cate et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells
US5639616A (en) Isolated nucleic acid encoding a ubiquitous nuclear receptor
Forman et al. c-erbA protooncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes
El-Ashry et al. Estrogen induction of TGF-α is mediated by an estrogen response element composed of two imperfect palindromes
Webster et al. The transcriptional activation function located in the hormone‐binding domain of the human oestrogen receptor is not encoded in a single exon.
US6680368B1 (en) Estrogen receptor beta
Chang et al. Molecular cloning of new human TR2 receptors: a class of steroid receptor with multiple ligand-binding domains
CA2223717A1 (fr) Hormones steroides modifiees pour therapie genique et leurs methodes d'utilisation
Cavailles et al. Cathepsin D gene of human MCF7 cells contains estrogen-responsive sequences in its 5′ proximal flanking region
WO1995029685A1 (fr) Antagonistes de l'activine utilises comme nouveaux contraceptifs
Stack et al. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells
EP0935657B1 (fr) Recepteurs d'hormones steroidiennes modifies
Horowitz et al. Characterization of the domain structure of chick c-erbA by deletion mutation: in vitro translation and cell transfection studies
Krett et al. Human progesterone A-receptors can be synthesized intracellularly and are biologically functional
Govindan et al. Human glucocorticoid receptor gene promotor—homologous down regulation
JPH08512197A (ja) 受容体アゴニストのスクリーニング方法
CA2222562A1 (fr) Procedes de depistage d'agonistes et d'antagonistes de recepteurs
Traish et al. Loss of expression of a 55 kDa nuclear protein (nmt55) in estrogen receptor-negative human breast cancer
US5571791A (en) Modified polypeptide fragments of the glucocorticoid receptor
EP1613572A2 (fr) Agoniste et antagoniste du recepteur de gpr54 utile dans le traitement de maladies associees a la gonadotrophine
Teng Lactoferrin gene promoter in human and mouse: Analogous and dissimilar characteristics
WO1989012687A1 (fr) Recepteur d'acide retinoique
Ruh et al. Estrogen receptor interaction with specific histones: Binding to genomic DNA and an estrogen response element

Legal Events

Date Code Title Description
FZDE Discontinued